<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Genet</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosgen</journal-id>
<journal-title-group>
<journal-title>PLOS Genetics</journal-title>
</journal-title-group>
<issn pub-type="ppub">1553-7390</issn>
<issn pub-type="epub">1553-7404</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pgen.1006374</article-id>
<article-id pub-id-type="publisher-id">PGENETICS-D-16-01162</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Fungi</subject><subj-group><subject>Cryptococcus</subject><subj-group><subject>Cryptococcus neoformans</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Fungal pathogens</subject><subj-group><subject>Cryptococcus neoformans</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Fungal pathogens</subject><subj-group><subject>Cryptococcus neoformans</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Mycology</subject><subj-group><subject>Fungal pathogens</subject><subj-group><subject>Cryptococcus neoformans</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Fungi</subject><subj-group><subject>Yeast</subject><subj-group><subject>Saccharomyces</subject><subj-group><subject>Saccharomyces cerevisiae</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Model organisms</subject><subj-group><subject>Yeast and fungal models</subject><subj-group><subject>Saccharomyces cerevisiae</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Lipids</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Fungal pathogens</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Fungal pathogens</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Mycology</subject><subj-group><subject>Fungal pathogens</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antifungals</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial control</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antifungals</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Mycology</subject><subj-group><subject>Antifungals</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Agriculture</subject><subj-group><subject>Agrochemicals</subject><subj-group><subject>Fungicides</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Physics</subject><subj-group><subject>Condensed matter physics</subject><subj-group><subject>Solid state physics</subject><subj-group><subject>Crystallography</subject><subj-group><subject>Crystal structure</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Database and informatics methods</subject><subj-group><subject>Biological databases</subject><subj-group><subject>Protein structure databases</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Molecular biology</subject><subj-group><subject>Macromolecular structure analysis</subject><subj-group><subject>Protein structure</subject><subj-group><subject>Protein structure databases</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Protein structure</subject><subj-group><subject>Protein structure databases</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>High-Resolution Genetics Identifies the Lipid Transfer Protein Sec14p as Target for Antifungal Ergolines</article-title>
<alt-title alt-title-type="running-head">Antifungal Ergolines Target Sec14p</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2493-6183</contrib-id>
<name name-style="western">
<surname>Filipuzzi</surname>
<given-names>Ireos</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Cotesta</surname>
<given-names>Simona</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Perruccio</surname>
<given-names>Francesca</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Knapp</surname>
<given-names>Britta</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Fu</surname>
<given-names>Yue</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Studer</surname>
<given-names>Christian</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Pries</surname>
<given-names>Verena</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Riedl</surname>
<given-names>Ralph</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Helliwell</surname>
<given-names>Stephen B.</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Petrovic</surname>
<given-names>Katarina T.</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Movva</surname>
<given-names>N. Rao</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Sanglard</surname>
<given-names>Dominique</given-names>
</name>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Tao</surname>
<given-names>Jianshi</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Hoepfner</surname>
<given-names>Dominic</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Institute of Microbiology, University of Lausanne and University Hospital Center, Lausanne, Switzerland</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Alspaugh</surname>
<given-names>J. Andrew</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Duke University School of Medicine, UNITED STATES</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>I have read the journal's policy and the authors of this manuscript have the following competing interests: IF, SC, FP, BK, YF, CS, VP, RR, SBH, KTP, NRM, JT and DH are employees of Novartis and may own stock in the company. DS is an employee of the University of Lausanne and declares no competing or financial interests.</p>
</fn>
<fn fn-type="con">
<p><list list-type="simple">
<list-item><p><bold>Conceptualization:</bold> IF SC VP DH.</p></list-item>
<list-item><p><bold>Data curation:</bold> KTP.</p></list-item>
<list-item><p><bold>Formal analysis:</bold> IF.</p></list-item>
<list-item><p><bold>Investigation:</bold> IF SC FP BK YF CS RR SBH KTP DS JT.</p></list-item>
<list-item><p><bold>Methodology:</bold> KTP DS.</p></list-item>
<list-item><p><bold>Project administration:</bold> NRM DH.</p></list-item>
<list-item><p><bold>Supervision:</bold> NRM DH.</p></list-item>
<list-item><p><bold>Validation:</bold> IF CS RR.</p></list-item>
<list-item><p><bold>Visualization:</bold> IF DH.</p></list-item>
<list-item><p><bold>Writing – original draft:</bold> IF DH.</p></list-item>
<list-item><p><bold>Writing – review &amp; editing:</bold> IF DS.</p></list-item></list></p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">ireos.filipuzzi@novartis.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>17</day>
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<month>11</month>
<year>2016</year>
</pub-date>
<volume>12</volume>
<issue>11</issue>
<elocation-id>e1006374</elocation-id>
<history>
<date date-type="received">
<day>25</day>
<month>5</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>9</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-year>2016</copyright-year>
<copyright-holder>Filipuzzi et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pgen.1006374"/>
<abstract>
<p>Invasive infections by fungal pathogens cause more deaths than malaria worldwide. We found the ergoline compound NGx04 in an antifungal screen, with selectivity over mammalian cells. High-resolution chemogenomics identified the lipid transfer protein Sec14p as the target of NGx04 and compound-resistant mutations in Sec14p define compound-target interactions in the substrate binding pocket of the protein. Beyond its essential lipid transfer function in a variety of pathogenic fungi, Sec14p is also involved in secretion of virulence determinants essential for the pathogenicity of fungi such as <italic>Cryptococcus neoformans</italic>, making Sec14p an attractive antifungal target. Consistent with this dual function, we demonstrate that NGx04 inhibits the growth of two clinical isolates of <italic>C</italic>. <italic>neoformans</italic> and that NGx04-related compounds have equal and even higher potency against <italic>C</italic>. <italic>neoformans</italic>. Furthermore NGx04 analogues showed fungicidal activity against a fluconazole resistant <italic>C</italic>. <italic>neoformans</italic> strain. In summary, we present genetic evidence that NGx04 inhibits fungal Sec14p and initial data supporting NGx04 as a novel antifungal starting point.</p>
</abstract>
<abstract abstract-type="summary">
<title>Author Summary</title>
<p>Emerging resistance to antibiotics led to an inglorious revival of infectious diseases. Furthermore, in the past 30 years, only one novel anti-fungal target has been discovered which was used to develop therapies against. Therefore pathogen-selective targets and knowledge about possible resistance determinants are of utmost importance to successfully develop new medicines. Here we describe the identification of anti-fungal ergolines, targeting the lipid transfer protein Sec14p, and inhibiting the growth of two clinical isolates of the pathogenic fungus <italic>Cryptococcus neoformans</italic>. Both, compound and target represent attractive points for further investigations: Sec14p as it differs significantly from the human homolog and as it has been implicated in fungal viability and pathogenicity, and, ergolines as they are used in the clinic against a variety of diseases demonstrating both efficacy and safety.</p>
</abstract>
<funding-group>
<funding-statement>The authors received no specific funding for this work.</funding-statement>
</funding-group>
<counts>
<fig-count count="5"/>
<table-count count="0"/>
<page-count count="19"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Severe invasive fungal infections (IFIs) are life-threatening and associated with high mortality [<xref ref-type="bibr" rid="pgen.1006374.ref001">1</xref>]. <italic>Candida albicans</italic> (mortality: 20–50%) [<xref ref-type="bibr" rid="pgen.1006374.ref002">2</xref>], <italic>Cryptococcus neoformans</italic> (mortality: 20–70%) [<xref ref-type="bibr" rid="pgen.1006374.ref003">3</xref>] and <italic>Aspergillus fumigatus</italic> (mortality: 50–90%) [<xref ref-type="bibr" rid="pgen.1006374.ref004">4</xref>] represent the major human fungal pathogens that have devastating effects on mostly, but not exclusively, immune compromised individuals such as HIV patients, premature infants, diabetics, chemotherapy patients, organ transplant recipients and aging people [<xref ref-type="bibr" rid="pgen.1006374.ref001">1</xref>, <xref ref-type="bibr" rid="pgen.1006374.ref005">5</xref>]. Currently marketed drugs suffer from limited efficacy and bioavailability, narrow species spectrum and high toxicity [<xref ref-type="bibr" rid="pgen.1006374.ref006">6</xref>, <xref ref-type="bibr" rid="pgen.1006374.ref007">7</xref>] and the development of novel drugs against fungal-selective protein targets is challenging due to the high evolutionary conservation between fungi and man. This results in a limited number of druggable nodes and thus restricted chemical matter [<xref ref-type="bibr" rid="pgen.1006374.ref008">8</xref>]. Only one new antifungal drug class to treat systemic infections has been approved in the US in the last three decades, the β-glucan synthase inhibitors echinocandins (reviewed in [<xref ref-type="bibr" rid="pgen.1006374.ref009">9</xref>]). Efficacy of echinocandins however is limited, as they suffer from poor bioavailability [<xref ref-type="bibr" rid="pgen.1006374.ref010">10</xref>]. New fungal-selective targets are thus needed to screen for novel chemotypes to fight these infections [<xref ref-type="bibr" rid="pgen.1006374.ref006">6</xref>, <xref ref-type="bibr" rid="pgen.1006374.ref008">8</xref>].</p>
<p>The virulence of <italic>C</italic>. <italic>neoformans</italic> is largely dependent on its secretion machinery, as many of the molecules required to exert its virulence are extracellular [<xref ref-type="bibr" rid="pgen.1006374.ref011">11</xref>, <xref ref-type="bibr" rid="pgen.1006374.ref012">12</xref>]. Secreted factors include the major polysaccharide building block of the capsule, enzymes involved in the assembly, maintenance and integrity of the cell wall as well as other proteins [<xref ref-type="bibr" rid="pgen.1006374.ref013">13</xref>–<xref ref-type="bibr" rid="pgen.1006374.ref017">17</xref>]. So far three Sec proteins, Sec4p, Sec6p and Sec14p, have been implicated in secretion of factors essential to virulence of <italic>C</italic>. <italic>neoformans</italic> [<xref ref-type="bibr" rid="pgen.1006374.ref012">12</xref>]. Among these three Sec proteins, the phosphatidylinositol and phosphatidylcholine transfer protein Sec14p is most likely druggable [<xref ref-type="bibr" rid="pgen.1006374.ref018">18</xref>], whereas Sec4p, a Rab family member, or Sec6p, an anchoring protein, represent by far more challenging target classes like GTPases and protein-protein interactions, respectively. Sec14p has been shown to be essential not only for virulence, but also for growth [<xref ref-type="bibr" rid="pgen.1006374.ref011">11</xref>], a dual role which makes this enzyme an attractive drug target. Here we show the characterization of a fungal Sec14p inhibitor by using a suite of genetic assays to de-convolute the mode of action of the screening hit, NGx04, prioritized due to an established track record of ergolines in medicine [<xref ref-type="bibr" rid="pgen.1006374.ref019">19</xref>–<xref ref-type="bibr" rid="pgen.1006374.ref025">25</xref>]. Chemogenomic profiling identified hypersensitivity and resistance of deletion strains related to the action of Sec14p. Saturating mutagenesis of the SEC14 gene identified four key residues that reduced NGx04 potency. All identified residues localized into the lipid-binding cavity of the Sec14 protein suggesting that NGx04 is an active-site inhibitor and competition with the Sec14p lipid substrates supported this hypothesis. Resistance-residue guided <italic>in silico</italic> docking of NGx04 into the lipid-binding cavity outlined critical sites for compound-protein interaction most of which are conserved in the protein sequence of the pathogen <italic>C</italic>. <italic>neoformans</italic> but not in the human homolog. Testing NGx04 against two clinical isolates of <italic>C</italic>. <italic>neoformans</italic> confirmed antifungal action and lack of pronounced cytotoxicity in human cells. Interestingly, the most potent NGx04 derivative was found to exert fungicidal activity against a strain resistant to fluconazole, a commonly used drug against cryptococcosis.</p>
<p>In summary, we present evidence that NGx04 inhibits fungal Sec14p and initial data supporting NGx04 as a novel antifungal starting point.</p>
</sec>
<sec id="sec002" sec-type="results">
<title>Results</title>
<sec id="sec003">
<title>Haploinsufficiency profiling (HIP) and homozygous profiling (HOP) of NGx04</title>
<p>A high-throughput screen of the Novartis compound archive against <italic>S</italic>. <italic>cerevisiae</italic> was performed to identify novel antifungal compounds [<xref ref-type="bibr" rid="pgen.1006374.ref026">26</xref>, <xref ref-type="bibr" rid="pgen.1006374.ref027">27</xref>]. The ergot-related compound NGx04 (<xref ref-type="fig" rid="pgen.1006374.g001">Fig 1A</xref>) was among the validated hits scoring an IC<sub>50</sub> &lt; 20 μM. Due to the long history of ergolines in medicine [<xref ref-type="bibr" rid="pgen.1006374.ref019">19</xref>–<xref ref-type="bibr" rid="pgen.1006374.ref025">25</xref>] this scaffold was selected for target identification by chemogenomic profiling [<xref ref-type="bibr" rid="pgen.1006374.ref026">26</xref>]. Haploinsufficiency profiling (HIP) and homozygous profiling (HOP) are gene-dosage-dependent methods that assess the effect(s) of compounds against potential targets encoded by the <italic>S</italic>. <italic>cerevisiae</italic> genome [<xref ref-type="bibr" rid="pgen.1006374.ref028">28</xref>]. HIP indicates pathways directly affected by the compound, whereas HOP, with both gene copies deleted, indicates synthetic lethality and identifies compensating pathways to those directly affected by the compound. Testing NGx04 at sub-lethal doses (8 μM) in two independent biological replicates and correlating the profiles as previously published [<xref ref-type="bibr" rid="pgen.1006374.ref026">26</xref>] identified the heterozygous deletion of <italic>SEC14</italic> to result in significantly reduced fitness compared to the rest of the genome-wide heterozygous deletion collection (HIP) (<xref ref-type="fig" rid="pgen.1006374.g001">Fig 1B</xref>). In contrast, heterozygous deletion of <italic>KES1</italic>, which encodes a protein that negatively regulates Sec14p-dependent secretion [<xref ref-type="bibr" rid="pgen.1006374.ref029">29</xref>, <xref ref-type="bibr" rid="pgen.1006374.ref030">30</xref>], resulted in increased fitness (<xref ref-type="fig" rid="pgen.1006374.g001">Fig 1B</xref>). Hypersensitivity of the heterozygous <italic>SEC14</italic> strain was found to be unique when analyzing the scores of these two strains in our database capturing profiles of &gt; 4000 diverse compounds (<xref ref-type="fig" rid="pgen.1006374.g001">Fig 1D</xref>). Chemical-synthetic interactions of NGx04 (HOP) were identified with homozygous deletions of the genes encoding the regulatory subunit (<italic>SRF1</italic>) and the catalytic subunit (<italic>SPO14</italic>) of Phospholipase D, a previously identified substrate of Sec14p [<xref ref-type="bibr" rid="pgen.1006374.ref031">31</xref>, <xref ref-type="bibr" rid="pgen.1006374.ref032">32</xref>], and <italic>ITR1</italic> (<xref ref-type="fig" rid="pgen.1006374.g001">Fig 1C</xref>), the major myo-inositol transporter in <italic>S</italic>. <italic>cerevisiae</italic> [<xref ref-type="bibr" rid="pgen.1006374.ref033">33</xref>]. Hypersensitivity of <italic>SEC14/sec14</italic>, <italic>srf1/srf1</italic>, <italic>spo14/spo14 or itr1/itr1</italic> and hyposensitivity of <italic>KES1/kes1</italic> against NGx04 was confirmed by titrating NGx04 across the deletion strains and comparing inhibition to the control stain <italic>ho/ho</italic> (<xref ref-type="fig" rid="pgen.1006374.g001">Fig 1E</xref> HIP and <xref ref-type="fig" rid="pgen.1006374.g001">Fig 1F</xref> HOP). Taken together, this data suggests that NGx04 interferes with cellular viability at the level of the phosphatidylinositol and phosphatidylcholine transfer protein Sec14p.</p>
<fig id="pgen.1006374.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pgen.1006374.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Chemogenomic profiling.</title>
<p><bold>Structure, haploinsufficiency profiling (HIP) and homozygous profiling (HOP) of NGx04.</bold> A) The structure of NGx04 is shown. B) HIP and C) HOP were performed around IC<sub>30</sub> (8 μM) in duplicates and the average of the profiles is shown. The MADL score is given on the y-axis and indicates how sensitive a particular deletion strain is to a given compound, compared to its no-drug control. The Z-score is given on the x-axis and is a statistical measure of how frequently a particular deletion strain is affected within the so far profiled compounds [<xref ref-type="bibr" rid="pgen.1006374.ref026">26</xref>]. Circles depict non-essential deletions, whereas squares essential deletions. Hyper-sensitive deletions are found bottom left and hyper-resistant deletions top right of the panels. D) Hypersensitivity of a heterozygous <italic>SEC14/sec14</italic> strain across 4011 diverse compounds (x-axis) is displayed as Z-score (y-axis). NGx04 (arrow) was found to exert the strongest effect. Validation of the hit candidates from HIP E), HOP F) was performed by single strain growth inhibition. The indicated strains were grown for 24 h in the presence of increasing concentrations of NGx04 and growth measured by turbidity (OD<sub>600</sub>). Duplicate values were determined and used for logistic regression. The calculated IC<sub>50</sub> values are displayed.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006374.g001" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec004">
<title>Functional variomics screen for NGx04-resistant mutants</title>
<p>To verify our findings from the chemogenomic profiling studies, a saturation mutagenesis screening approach [<xref ref-type="bibr" rid="pgen.1006374.ref034">34</xref>] was used and supported Sec14p as the target of NGx04. A pool containing approximately 10<sup>5</sup> plasmid-based, mutagenized Sec14p-variants [<xref ref-type="bibr" rid="pgen.1006374.ref034">34</xref>] was plated onto solid growth media supplemented with 150 μM NGx04, a concentration that prevented colony formation of wild-type cells. Eighty-eight surviving colonies were isolated, plasmid DNA encoding the Sec14 proteins isolated and sequenced. This approach yielded mutations in four distinct amino acids of Sec14p: Y111H (identified 14 times), Y151H/S (identified 27 times), V154I (identified 15 times) and S173A/P/L (identified 32 times) (<xref ref-type="fig" rid="pgen.1006374.g002">Fig 2A</xref>). To confirm that the mutations were the resistance-defining factors, the plasmids containing the <italic>SEC14</italic> mutants were retransformed into wild type yeast. A plasmid containing the wild type copy of <italic>SEC14</italic> was used as control to exclude resistance due to <italic>SEC14</italic> gene copy-number effects. Spotting for single colony formation on lethal doses of NGx04 (<xref ref-type="fig" rid="pgen.1006374.g002">Fig 2B</xref>) as well as growth inhibition titrations (<xref ref-type="fig" rid="pgen.1006374.g002">Fig 2C</xref>) revealed that each of the four identified mutations was sufficient to confer resistance to NGx04. As the cells contained also the endogenous wild type <italic>SEC14</italic> allele this data revealed that the drug resistance was dominant and provided further support that Sec14p is the growth inhibitory target of NGx04.</p>
<fig id="pgen.1006374.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pgen.1006374.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Resistance mapping.</title>
<p><bold>Functional variomics screen for NGx04-resistant mutants.</bold> A) The SEC14 ORFs of 88 NGx04-resistant colonies were amplified by PCR and sequenced. Four mutations mapping to the lipid-binding part of Sec14p were found. The identified amino acid changes with their respective frequencies are given. B) The plasmids coding for various SEC14 proteins were re-transformed into a fresh wild type yeast strain and serial dilutions of the cultures spotted on either 150 μM of NGx04 or DMSO control, incubated for 3 days at 30°C and scored for growth. C) The strains were grown for 24 h in the presence of increasing concentrations of NGx04 and growth measured by turbidity (OD<sub>600</sub>). Duplicate values were determined and the 18 h time point was used for logistic regression. The calculated IC<sub>50</sub> values displayed.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006374.g002" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec005">
<title>Phosphatidylinositol (PI) and phosphatidylcholine (PC) competition</title>
<p>Crystal structures of Sec14p and Sec14p-like proteins from various species including <italic>S</italic>. <italic>cerevisisae</italic> (PDB ID: 1AUA) and human (PDB ID: 1OLM) have been solved. Although the lipid-binding pocket of the enzyme is well characterized [<xref ref-type="bibr" rid="pgen.1006374.ref035">35</xref>–<xref ref-type="bibr" rid="pgen.1006374.ref037">37</xref>] Sec14p has not been crystalized when bound to phosphatidylethanolamine (PtdEtn) substrate. The crystal structure of the S. cerevisisae Sfh1protein (PDB ID: 3B7Q), sharing 62.3% identity with Sec14p, shows that phosphatidylcoline (PC) hydrophobic tail forms van der Waals interactions with a cluster of hydrophobic residues, whereas the phosphate moiety is interacting with the side-chain hydroxyl groups of residues S175 and T177, and the nitrogen contacts the phenolic oxygen of Y113 (<xref ref-type="fig" rid="pgen.1006374.g003">Fig 3A</xref>). Since the NGx04 resistance-conferring residues were located in the equivalent catalytic site of Sec14p (<xref ref-type="fig" rid="pgen.1006374.g003">Fig 3A</xref>) (i.e. S173, corresponding to S175, and T175 to T177 in Sfh1, two residues involved in H-bonds with PC) we reasoned that NGx04 would bind in the lipid-binding pocket of the protein.</p>
<fig id="pgen.1006374.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pgen.1006374.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Active site antagonism.</title>
<p><bold>Phosphatidylinositol (PI) and phosphatidylcholine (PC) competition.</bold> A) The crystal structure of Phosphatidylcholine (PC) bound to the yeast Sfh1protein (PDB ID: 3B7Q), (where R is oleoyl and R’ is palmitol). PC hydrophobic tail forms van der Waals interactions with a cluster of hydrophobic residue, whereas the phosphate moiety is interacting with the side-chain hydroxyl groups of residues S175 and T177, and the ethanolamine nitrogen contacts the phenolic oxygen of Y113. B) The proposed docking pose of NGx04 in the putative binding site of the yeast protein structure is shown (PDB ID:1AUA). In the suggested binding mode, the ester moiety of the ligand forms a hydrogen bond with Y111 while the ergoline amine forms H-bonds with the T175. The ergoline moiety is also forming van der Waals interactions with the following residues: Y122, Y151, S173, M177 and F212. C) Wild type yeast was grown in presence of increasing concentrations of NGx04, supplemented with either 200 μM PI, 200 μM PC or no phospholipid, incubated at 30°C and growth followed over time by measuring turbidity (OD<sub>600</sub>). Duplicate values were determined and the time points at 18 h were used for logistic regression.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006374.g003" xlink:type="simple"/>
</fig>
<p>To test this hypothesis, the <italic>S</italic>. <italic>cerevisisae</italic> x-ray structure of Sec14p was used to dock the NGx04 ligand into the lipid-binding cavity (<xref ref-type="fig" rid="pgen.1006374.g003">Fig 3B</xref>). In the resulting docking model, the ester moiety of the ligand formed an H-bond with Y111 while the ergoline amine formed an H-bond with T175. The ergoline moiety also made van der Waals interactions with the residues Y122, Y151, S173, M177 and F212. The calculated docking model was in agreement with the experimental data from the mutagenesis study, as three of the four identified resistance conferring mutations were directly involved in ligand interactions (Y111, Y151 and S173) and the identified V154 residue, although not directly involved in ligand interactions, was only 4.5 Å away from NGx04. The model outlines that a larger residue at this position like Isoleucine would be deleterious for ligand binding. As our docking experiment was biased towards the lipid-binding cavity we aimed at further supporting evidence for NGx04 binding in this protein pocket. To do so we tested if NGx04 would compete for phospholipid-binding in the Sec14p cavity. Wild type <italic>S</italic>. <italic>cerevisiae</italic> cells were grown in presence of increasing doses of NGx04 in medium containing an excess of either phosphatidylinositol (PI) or phosphatidylcholine (PC) (200 μM). Both lipids, PI and PC, were found to alleviate NGx04-mediated growth inhibition, supporting a competitive mode of inhibition at the lipid-binding cavity of Sec14 (<xref ref-type="fig" rid="pgen.1006374.g003">Fig 3C</xref>).</p>
</sec>
<sec id="sec006">
<title>Mammalian cell proliferation and cytotoxicity of NGx04</title>
<p>One key requirement of antifungal medicines is selective inhibition of the pathogen over the mammalian host. To explore potential undesired activity of NGx04 against mammalian cells we used the Cancer Cell Line Encyclopedia CCLE, a collection of 512 human cancer cell lines (broadinstitute.org/ccle). Dose-response curves for NGx04 were generated in a proliferation assay and IC<sub>50</sub> values determined. Although a large number of anti-proliferative compounds were published to be active across the CCLE collection [<xref ref-type="bibr" rid="pgen.1006374.ref038">38</xref>, <xref ref-type="bibr" rid="pgen.1006374.ref039">39</xref>] only one fourth of the cell lines was found to be sensitive to NGx04 as defined by Amax &lt;50% and IC<sub>50</sub> &lt;30 μM. Furthermore the large majority of cells (76%) were not notably affected by NGx04 (<xref ref-type="fig" rid="pgen.1006374.g004">Fig 4A</xref>). Since HepG2 cells are known to be a suitable tool to profile toxicity of compounds [<xref ref-type="bibr" rid="pgen.1006374.ref040">40</xref>], we used this liver-derived line to assess cytotoxicity of NGx04. A dose-response curve was generated and an IC<sub>50</sub> value of 157.6 μM determined by logistic regression (<xref ref-type="fig" rid="pgen.1006374.g004">Fig 4B</xref>), again indicating potential selectivity of NGx04 for the fungal protein. Superimposition of the <italic>S</italic>. <italic>cerevisisae</italic> Sec14p crystal structure (PDB ID: 1AUA, blue) and the crystal structure of the human orthologue SEC14L2 (PDB ID: 1OLM, green) (<xref ref-type="fig" rid="pgen.1006374.g004">Fig 4C</xref>) revealed that although having a similar overall structure fold, the active site of the two enzymes differ considerably. 16 of 21 amino acid residues within a 5 Å radius from any atom of the docked Ngx04 ligand were not conserved between the two proteins. Critical differences in the active site of the human protein are the residues F178, C128, I151 and L186 (corresponding to S201, Y151, T175 and M209 in yeast) which form a smaller and more hydrophobic pocket compared to the yeast protein (<xref ref-type="fig" rid="pgen.1006374.g004">Fig 4C</xref>). Visualizing the solvent accessible surface of the human Sec14p with NGx04 as a potential ligand revealed that NGx04 is too big to occupy this smaller binding pocket (see clear ligand bumps towards the solvent accessible surface) (<xref ref-type="fig" rid="pgen.1006374.g004">Fig 4D</xref>). In addition, all four NGx04-interacting amino acids identified by functional variomics are missing in the human enzyme (<xref ref-type="supplementary-material" rid="pgen.1006374.s001">S1 Fig</xref>). In summary, it is plausible that the observed lack of potent activity of NGx04 against human cell lines can be explained by differences in the catalytic pocket and the absence of proposed NGx04 interacting residues in the human protein.</p>
<fig id="pgen.1006374.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pgen.1006374.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Fungal selectivity.</title>
<p><bold>Mammalian cell growth inhibition and cytotoxicity of NGx04.</bold> A) Dose-response curves for NGx04 were generated in growth inhibition assay and IC<sub>50</sub> values determined in duplicates [<xref ref-type="bibr" rid="pgen.1006374.ref039">39</xref>]. IC<sub>50</sub> values and growth inhibition (Amax) are displayed. 76% of the tested cell lines were not significantly inhibited by NGx04. B) A dose-response curves for NGx04 was generated in a MTS cytotoxicity assay using HepG2 cells in triplicates and a toxicity curve generated by logistic regression. C) Overlay of the crystal structure of the yeast Sec14p (PDB ID: 1AUA, protein structure highlighted in blue) and its human orthologue SEC14L2 (PDB ID: 1OLM, protein structure highlighted in green) reveals that the amino acid residues belonging to the putative binding site are not conserved between the yeast and the human protein. D) Overlay of the docked NGx04 in the yeast Sec14p (PDB ID: 1AUA) and its human orthologue SEC14L2 (PDB ID: 1OLM). The amino acid residues of the yeast protein structure have been hidden whereas the surface of the putative binding site of the human protein structure has been added to highlight the difference in the overall shape between the active site of the two species.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006374.g004" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec007">
<title><italic>C</italic>. <italic>neoformans</italic> growth inhibition by NGx04 scaffolds</title>
<p>Sec14p is reported to be essential for virulence as well as for growth in <italic>C</italic>. <italic>neoformans</italic> [<xref ref-type="bibr" rid="pgen.1006374.ref011">11</xref>, <xref ref-type="bibr" rid="pgen.1006374.ref012">12</xref>]. The <italic>S</italic>. <italic>cerevisiae</italic> and <italic>C</italic>. <italic>neoformans</italic> proteins show 53% similarity by pair-wise alignment with higher conservation of the residues in the lipid-binding pocket (<xref ref-type="supplementary-material" rid="pgen.1006374.s002">S2 Fig</xref>). Furthermore, three of the four sites identified to be critical for NGx04 sensitivity, are conserved (<xref ref-type="supplementary-material" rid="pgen.1006374.s002">S2 Fig</xref>). In combination with the current high unmet medical need related to <italic>Cryptococcus</italic> infections we prioritized testing of NGx04 and 18 related ergoline scaffold analogs against this pathogen. Two clinical isolates of <italic>C</italic>. <italic>neoformans</italic> (ATCC 36556 and ATCC 90113) were plated in triplicates on increasing drug concentrations and MIC-2 (50% inhibition) and MIC-0 (no visible fungal growth) concentrations were scored after 72 hrs. (<xref ref-type="fig" rid="pgen.1006374.g005">Fig 5</xref>). NGx04 and analogues including NGx03, NGx16, NGx07, NGx09 and NGx19 were found to inhibit <italic>C</italic>. <italic>neoformans</italic> growth in the tested dose range. NGx03 appeared to be the most potent compound against ATCC 36556 with a MIC-2 of 3.13 μg/ml and a MIC-0 of 6.25 μg/ml whereas NGx19 showed a broader spectrum with a MIC-2 of 12.5μg/ml against the first isolate and a MIC-2 of 6.25μg/ml against the second strain.</p>
<fig id="pgen.1006374.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pgen.1006374.g005</object-id>
<label>Fig 5</label>
<caption>
<title>Antifungal testing.</title>
<p><bold><italic>C</italic>. <italic>neoformans</italic> growth inhibition by NGx04 scaffolds.</bold> NGx04 and close analogues were tested against <italic>C</italic>. <italic>neoformans</italic> ATCC 36556 and ATCC 90113 in a 72 h proliferation assay and MIC-2 (50% inhibition) and MIC-0 (no visible fungal growth) determined. Triplicate values are given in μg/ml. Amphotericin B was included as positive control.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006374.g005" xlink:type="simple"/>
</fig>
<p>Fluconazole (FLU) is commonly used to treat cryptococcosis [<xref ref-type="bibr" rid="pgen.1006374.ref041">41</xref>]. Repeated exposure or prolonged treatment with azoles, however, can lead to resistance [<xref ref-type="bibr" rid="pgen.1006374.ref042">42</xref>–<xref ref-type="bibr" rid="pgen.1006374.ref044">44</xref>]. We thus tested the ability of the most potent compounds to inhibit growth of the FLU-resistant <italic>C</italic>. <italic>neoformans</italic> strain BPY22 [<xref ref-type="bibr" rid="pgen.1006374.ref045">45</xref>] and found activity for NGx03 (MIC-2 of 16 μg/ml and MIC-0 of 32 μg/ml) and weaker activity for NGx16 and NGx19 (<xref ref-type="supplementary-material" rid="pgen.1006374.s003">S3 Fig</xref>), indicating the potential of ergolines to fight FLU-resistant <italic>C</italic>. <italic>neoformans</italic>. We next assessed the mechanism of inhibition, since fungicidal agents, compared to fungistatic agents [<xref ref-type="bibr" rid="pgen.1006374.ref046">46</xref>], are associated with decreased mortality and found NGx03 and NGx16 to exhibit a fungicidal effect on FLU-sensitive and FLU-resistant <italic>C</italic>. <italic>neoformans</italic> strains (<xref ref-type="supplementary-material" rid="pgen.1006374.s006">S6 Fig</xref>). NGx03 was among the most active compound when tested in susceptibility assays and thus corroborates with its fungicidal effect in the tested strains.</p>
<p>Analysis of the structure-activity relationship (SAR) of the tested ergolines (<xref ref-type="fig" rid="pgen.1006374.g005">Fig 5</xref>) revealed that analogues where the aromatic amino group was substituted by a 2,2,2-trichloroethyl-carboxylate moiety scored anti-fungal activity (NGx03 and NGx07), while the analogues with an unsubstituted, acetylated or formulated aromatic amino group lacked notable activity. Nitro substitution of the aromatic ring appeared to be tolerated in all positions as the analogue without any substituent was found to be equipotent. In summary, antifungal activity against <italic>C</italic>. <italic>neoformans</italic> as predicted by the analysis of identified NGx04 interacting residues could experimentally be confirmed. Our limited SAR experiment identified that building off the aromatic ring was tolerated enabling future medicinal chemistry approaches with the aim to assess and optimize potency, spectrum and other pharmacokinetic parameters of this scaffold.</p>
</sec>
</sec>
<sec id="sec008" sec-type="conclusions">
<title>Discussion</title>
<p>Severe IFIs are often life-threatening conditions. The clinical anti-fungal arsenal however is very limited and the β-glucan synthase inhibitor echinocandin is the only drug developed over the last three decades that modulates a novel target. In addition, the emergence of resistance against established treatments dramatically emphasizes the importance of identifying novel and selective drug targets. <italic>C</italic>. <italic>neoformans</italic> is the most common cause of fungal meningitis (reviewed in [<xref ref-type="bibr" rid="pgen.1006374.ref047">47</xref>], and the invasion of the central nervous system by <italic>C</italic>. <italic>neoformans</italic> is strictly dependent on the secretion of proteins like phospholipase B1 (Plb1) [<xref ref-type="bibr" rid="pgen.1006374.ref011">11</xref>], the metalloprotease Mpr1 [<xref ref-type="bibr" rid="pgen.1006374.ref048">48</xref>], building blocks of the capsule, and enzymes involved in the assembly, maintenance and integrity of the cell wall as well as other proteins [<xref ref-type="bibr" rid="pgen.1006374.ref012">12</xref>] [<xref ref-type="bibr" rid="pgen.1006374.ref049">49</xref>]. Protein traffic and secretion in <italic>C</italic>. <italic>neoformans</italic> has been described to occur via more than one pathway involving either Sec4p, Sec6p or Sec14p [<xref ref-type="bibr" rid="pgen.1006374.ref012">12</xref>], where the secretion of the key cryptococcal virulence factor Plb1 is strictly Sec14p-dependent [<xref ref-type="bibr" rid="pgen.1006374.ref011">11</xref>]. Of the three Sec proteins involved, the phosphatidylinositol and phosphatidylcholine transfer protein Sec14p represents the most promising target, with the first inhibitory scaffold published recently [<xref ref-type="bibr" rid="pgen.1006374.ref018">18</xref>]. Sec4p, a Rab family GTPase, is very difficult to target, and several pharmaceutical laboratories failed in the past to identify selective molecules against this target family. Sec6p, an essential subunit of the exocyst complex is a structural protein which could be modulated by interfering with its interactions to binding partners, however, tackling protein-protein interactions is difficult and often yields only very limited success.</p>
<p>Genomic fitness analysis has proven to be a powerful approach for mode of action elucidation of test compounds [<xref ref-type="bibr" rid="pgen.1006374.ref026">26</xref>, <xref ref-type="bibr" rid="pgen.1006374.ref028">28</xref>, <xref ref-type="bibr" rid="pgen.1006374.ref050">50</xref>–<xref ref-type="bibr" rid="pgen.1006374.ref052">52</xref>]. Whereas haploinsufficiency profiling (HIP) can directly identify the target of a test compound, homozygous profiling (HOP) identifies synthetic lethal and compensatory interactions. Follow up work of a large high-throughput screening campaign by HIP HOP identified NGx04 as a potential Sec14p inhibitor. No chemical probe, interfering with either Sec4p or Sec6p was found among the ca 4,000 acquired compound profiles. The heterozygous <italic>SEC14</italic> deletion showed dramatically reduced fitness at sub-lethal NGx04 doses (HIP), indicating that reducing Sec14p expression represents the main action of NGx04. Interestingly, the heterozygous deletion of Kes1p, a protein which negatively regulates Sec14p-dependent secretion [<xref ref-type="bibr" rid="pgen.1006374.ref029">29</xref>, <xref ref-type="bibr" rid="pgen.1006374.ref030">30</xref>], led to increased fitness as deletion of a repressor appeared to activate the pathway. The homozygous deletions of the regulatory subunit (Srf1p) and the catalytic subunit (Spo14p) of PLD were found to be synthetic lethal with inhibiting Sec14p by NGx04. PLD was described to bypass Sec14 mutations [<xref ref-type="bibr" rid="pgen.1006374.ref053">53</xref>] by generating a phosphatidic acid pool that is utilized in supporting yeast Golgi secretory function. In addition, deletion of Itr1p, a Myo-inositol sugar transporter, was also found to be synthetic lethal with Sec14p inhibition, probably by depletion of inositol levels in the cell. Thus, our data indicate that NGx04 interferes with Sec14p directly or might modulate a Sec14p-dependent process.</p>
<p>Target identification and validation by resistance cloning has often been successful since mutations in the drug binding pocket of the target can lead to lack of drug binding and thus resistance. Spontaneous or chemically induced, random mutations were historically screened for resistance followed by cloning of the responsible single nucleotide polymorphism (SNP) [<xref ref-type="bibr" rid="pgen.1006374.ref054">54</xref>]. An elegant variation of the approach has been published and termed <italic>functional variomics</italic> [<xref ref-type="bibr" rid="pgen.1006374.ref034">34</xref>]. The functional variomics tool consists of a (nearly) genome-wide collection of plasmid-based SNPs. Over 90% of the yeast ORFs are represented as pools of 10,000 to 100,000 different SNPs. Plating the functional variomics pool of <italic>SEC14</italic> at inhibitory concentrations of NGx04, led to the identification of four distinct SNPs, isolated multiple times. Plating the genome-wide functional variomics pool, led to the identification of only <italic>SEC14</italic>-related mutations (<xref ref-type="supplementary-material" rid="pgen.1006374.s004">S4 Fig</xref>), supporting that Sec14p is the efficacy target of NGx04. All isolated SEC14 SNPs, Y111H, Y151H/S, V154I and S173A/P/L, located to the lipid-binding pocket of Sec14p, indicating that NGx04 was a substrate-competitive Sec14p inhibitor. Crystal structures of Sec14 proteins from various species, including <italic>S</italic>. <italic>cerevisiae</italic> [<xref ref-type="bibr" rid="pgen.1006374.ref055">55</xref>], have been solved and the lipid-binding pocket of the enzyme is well characterized [<xref ref-type="bibr" rid="pgen.1006374.ref035">35</xref>–<xref ref-type="bibr" rid="pgen.1006374.ref037">37</xref>]. The residues S173 and T175 are involved in the coordination of the phosphate moiety whereas the phenolic oxygen of Y111 binds the nitrogen the substrate PtdEtn. As Y111H and S173A give resistance to NGx04, we postulated that the compound competes for substrate binding which we showed by PI- and PC-mediated suppression of NGx04-induced growth inhibition. The observed dominant resistance by single mutations is a concern when considering NGx04as an anti-fungal lead compound. However, advanced knowledge on privileged sites than can confer resistance is valuable information and we believe that a medicinal chemistry program paralleled by the functional variomics approach will allow the further optimization of NGx04-derived compounds with favorable resistance profiles.</p>
<p>As a precursor for <italic>in vivo</italic> toxicology studies we assessed the potential of NGx04 to inhibit proliferation of human cells by determining IC<sub>50</sub> values across the Cancer Cell Line Encyclopedia. Most of the tested lines were not found to be significantly sensitive and, in addition, a HepG2-based cytotoxicity assay confirmed this finding. Genetic complementation of an <italic>S</italic>.<italic>cerevisiae</italic> SEC14 homozygous deletion by human SEC14 failed in our hands (<xref ref-type="supplementary-material" rid="pgen.1006374.s005">S5 Fig</xref>), probably due to evolutionary divergence. Although the lipid transfer function of Sec14 proteins has been conserved during evolution, structural differences are found between the <italic>S</italic>. <italic>cerevisiae</italic> and human proteins [<xref ref-type="bibr" rid="pgen.1006374.ref056">56</xref>]. The two proteins show a similar overall protein fold, however, specific differences are found in the lipid-binding pocket where amino acids critical for NGx04 binding are not conserved between the human and the fungal proteins [<xref ref-type="bibr" rid="pgen.1006374.ref057">57</xref>]. These differences affect the overall shape of the putative binding site, forming a smaller binding pocket in the human active site. A <italic>C</italic>. <italic>neoformans</italic> Sec14p structure is needed to further exploit species-specific features and guide medicinal chemistry. Aligning <italic>S</italic>.<italic>cerevisiae</italic> SEC14 to <italic>C</italic>. <italic>neoformans</italic> SEC14-1 and SEC14-2 shows that most residues involved in NGx04 binding as well as responsible for mutation-based resistance are conserved (Y111, Y122, Y151, S173 and T175) (<xref ref-type="supplementary-material" rid="pgen.1006374.s002">S2 Fig</xref>), suggest that NGx04 binds to the two fungal proteins in a very similar way.</p>
<p><italic>In vitro</italic> activity against two clinical isolates of <italic>C</italic>. <italic>neoformans</italic> was assessed. NGx04 scored anti-cryptococcal activity and more potent derivatives were identified. Substitutions of the aromatic amino group of the scaffold were found to be critical for its anti-fungal activity, whereas other residues had less effect. Two features seem to determine potency of the compound class, the chlorinated carbamate and the aromatic amide (NGx03 and NGx07). NGx03 having both, an aromatic amide and additionally a trifluoromethyl substituted phenyl, displays the highest activity. The data density obtained by the limited SAR by inventory did not allow the building of a high-resolution pharmacophore template. However, tolerated substitutions of the aromatic ring system demonstrated that NGx04 is amenable to derivatization and comprises an attractive starting point for a medicinal chemistry program. In addition, NGx03 was also found to inhibit growth of a FLU-resistant <italic>C</italic>. <italic>neoformans</italic> strain (<xref ref-type="supplementary-material" rid="pgen.1006374.s003">S3 Fig</xref>) and furthermore the effect was found to be cidal <xref ref-type="supplementary-material" rid="pgen.1006374.s006">S6 Fig</xref>), underlining the potential of ergolines to fight <italic>C</italic>. <italic>neoformans</italic> infections.</p>
<p>Some of the compounds presented here were also tested against <italic>C</italic>. <italic>albicans</italic> (ATCC 24433), <italic>A</italic>. <italic>fumigatus</italic> (ATCC MYA-3627), R. oryzae (ATCC MYA-4621) and <italic>F</italic>. <italic>solani</italic> (ATCC MYA-3636), but found to be inactive (<xref ref-type="supplementary-material" rid="pgen.1006374.s008">S8 Fig</xref>). Since the fungal Sec14 proteins are evolutionary conserved, targeting Sec14p seems only to be efficacious in <italic>C</italic>. <italic>neoformans</italic>. Sec14p-dependent virulence has only been described for <italic>C</italic>. <italic>neoformans</italic> [<xref ref-type="bibr" rid="pgen.1006374.ref011">11</xref>] but not for other fungal pathogen. It remains to be seen if in the future intervening at different nodes of the cellular lipid transfer pathway might yield novel anti-fungal targets.</p>
<p>From a chemical perspective one might suspect some NGx side groups to be potentially reactive. We thus tested the cryptococcal active compounds in a rat liver microsome-based assay for metabolic stability but could not detect significant degradation (<xref ref-type="supplementary-material" rid="pgen.1006374.s007">S7 Fig</xref>). In addition, potent activity in rich medium (containing crude cell extracts) and the absence of any cell-wall/plasma membrane-stress indicative hits in HIP and HOP [<xref ref-type="bibr" rid="pgen.1006374.ref026">26</xref>, <xref ref-type="bibr" rid="pgen.1006374.ref058">58</xref>], support the notion that this scaffold is stable and selectively targeting Sec14p.</p>
<p>Invasion of the central nervous system by <italic>C</italic>. <italic>neoformans</italic> is a prerequisite for fungal meningitis. We thus performed artificial membrane permeability assays in order to assess the potential of the cryptococcal active compounds to penetrate the blood brain barrier (<xref ref-type="supplementary-material" rid="pgen.1006374.s007">S7 Fig</xref>). All tested compounds, with the exception of NGx13, showed high permeability indicating a potential exposure of the CNS. High permeability of ergolines is expected, as members of the ergoline class are used as psychedelic narcotics since their discovery.</p>
<p>Although hallucinogenic and toxic effects of ergot alkaloids are known since 600 BC [<xref ref-type="bibr" rid="pgen.1006374.ref059">59</xref>], a first representative was isolated only in 1875 [<xref ref-type="bibr" rid="pgen.1006374.ref060">60</xref>]. Today, over 80 ergot alkaloids from fungi and plants have been described [<xref ref-type="bibr" rid="pgen.1006374.ref061">61</xref>] and a number non-hallucinogenic ergolines, or their derivatives, are used in the clinic to treat Parkinson’s disease, acromegaly, hyperprolactinemia, restless-legs syndrome, hypotony, migraine and other diseases (summarized by [<xref ref-type="bibr" rid="pgen.1006374.ref061">61</xref>]). Interestingly, the effects of this substance class are exclusively transmitted via α-adreno-, serotonin- or dopamine receptors in mammals [<xref ref-type="bibr" rid="pgen.1006374.ref062">62</xref>]. Identification of NGx04 as Sec14p inhibitor not only provides the first report of ergolines as non-GPCR modulators, but also the first activity of ergolines on lower eukaryotes.</p>
</sec>
<sec id="sec009" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="sec010">
<title>Compound handling</title>
<p>Compounds were stored as powders until use. Prior to testing compounds were dissolved as 10 mM stocks into 90% DMSO and kept at 4°C for a maximum of 6 months. Purity and integrity was analyzed by LC-MS/MS and UV. Solutions only passed QC if corresponding mass could be identified and the main component concentration was above 85%.</p>
</sec>
<sec id="sec011">
<title><italic>S</italic>. <italic>cerevisiae</italic> strains</title>
<p>The heterozygous and homozygous deletion strain collections were acquired (OpenBiosystems YSC1055 and YSC1056) and pools generated as described previously [<xref ref-type="bibr" rid="pgen.1006374.ref063">63</xref>]. The functional variomics collection was obtained from Dr. X. Pan (Baylor College of Medicine, Houston, TX 77030, USA).</p>
</sec>
<sec id="sec012">
<title><italic>C</italic>. <italic>neoformans</italic> strains</title>
<p><italic>C</italic>. <italic>neoformans</italic> strains ATCC 36556, a lung isolate, and ATCC 90113, a cerebrospinal fluid isolate, were purchased from ATCC, Manassas, VA (USA). BPY22 was obtained from [<xref ref-type="bibr" rid="pgen.1006374.ref045">45</xref>].</p>
</sec>
<sec id="sec013">
<title>Haploinsufficiency profiling (HIP) and homozygous profiling (HOP)</title>
<p>Genomic profiling and microarray analysis were performed as described previously [<xref ref-type="bibr" rid="pgen.1006374.ref026">26</xref>].</p>
</sec>
<sec id="sec014">
<title>Functional variomics screen</title>
<p>The functional variomics screen was performed as described previously [<xref ref-type="bibr" rid="pgen.1006374.ref034">34</xref>] with the difference that plasmids of resistant clones were analyzed by Sanger sequencing and not chip hybridization: Clones were picked and grown over night in 1 ml of YPD at 30°C in a 96 deep well block. Cells were then subsequently washed with distilled water and subjected to a zymolyase treatment prior to purification of plasmid DNA by Wizard SV DNA purification system (Promega)</p>
</sec>
<sec id="sec015">
<title>Phosphatidylinositol (PI) and phosphatidylcholine (PC) competition</title>
<p><italic>S</italic>. <italic>cerevisiae</italic> BY4741 (Open Biosystems) was grown in YPD medium in the absence or presence of additional phosphatidylinositol or phosphatidylcholine (200 μM each, Sigma-Aldrich 79401 or P3556, respectively). OD600 values of exponentially growing yeast cultures were recorded with a robotic system. Twelve-point serial dilutions were assayed in 96-well plates with a reaction volume of 150 μl.</p>
</sec>
<sec id="sec016">
<title>Crystal structure docking</title>
<p>The <italic>S</italic>. <italic>cerevisiae</italic> protein structure (PDB ID 1AUA) has been prepared using the default settings of the ProteinPreparation Wizard within the Maestro Schrödinger Suite (<ext-link ext-link-type="uri" xlink:href="http://www.schrodinger.com/" xlink:type="simple">www.schrodinger.com</ext-link>). Ligand coordinates have been generated with Corina [<xref ref-type="bibr" rid="pgen.1006374.ref064">64</xref>]. This conformation has been used as a starting point for the docking. The docking procedure was carried out using Glide SP within the Maestro Schrödinger Suite. After docking the complex protein-ligand has been minimized using MacroModel within the Maestro Schrödinger Suite, allowing the ligand to be flexible and keeping the protein rigid.</p>
</sec>
<sec id="sec017">
<title>Mammalian cell growth inhibition</title>
<p>Profiling across the Cancer Cell Line Encyclopedia was performed as described previously [<xref ref-type="bibr" rid="pgen.1006374.ref065">65</xref>]. MTS toxicity was determined using a CellTiter 96 AQ<sub>ueous</sub> One Solution Cell Proliferation Assay kit from Peomega.</p>
</sec>
<sec id="sec018">
<title><italic>C</italic>. <italic>neoformans</italic> growth inhibition</title>
<p>Antifungal susceptibility testing was conducted according to the Clinical and Laboratory Standards Institute (CLSI) guidelines for broth microdilution assay M27-A3. Testing was performed in RPMI-1640 (HyClone) with 2.05 mM glutamine, phenol red, without bicarbonate and buffered with 0.165 mol/l 3-(N-morpholino) propanesulfonic acid (MOPS). The medium was adjusted to pH 7.0 and sterilized with a 0.2 μm filter. Two endpoints were recorded: MIC-0 (complete inhibition with no visible fungal growth) and MIC-2 (prominent inhibition corresponding to &gt;50% growth reduction).</p>
</sec>
<sec id="sec019">
<title>Fungicidal vs fungistatic drug testing</title>
<p>To test the fungistatic or fungicidal effect of the ergolines, the format of the CLSI susceptibility assay was followed. Briefly, <italic>C</italic>. <italic>neoformans</italic> strains were grown overnight in YEPD medium at 30°C under constant agitation. Cells were then diluted to about 10<sup>3</sup> cells/ml in RPMI medium as starting inoculum and 200 μl of this inoculum was pipetted in 96- well flat bottom microtiter plate. The starting inoculum was subjected to CFU counts in YEPD agar by plating serial dilutions and 48 hrs. incubation. Drugs were diluted to a final concentration of 16μg/ml and MIC-0 values determined by the CLSI protocol. After an incubation of 24 hrs. at 35°C, cells were diluted in RPMI and plated onto YEPD agar for CFU counting. A fungicidal effect was defined as decreased CFUs in drug-exposed cultures as compared to CFUs in the starting inoculum.</p>
</sec>
<sec id="sec020">
<title>Rat liver microsome and artificial membrane permeability assay</title>
<p>Metabolic stability was determined as described previously [<xref ref-type="bibr" rid="pgen.1006374.ref066">66</xref>] on a fully automated platform, the artificial membrane permeability assays was performed as described previously [<xref ref-type="bibr" rid="pgen.1006374.ref067">67</xref>]</p>
</sec>
</sec>
<sec id="sec021">
<title>Supporting Information</title>
<supplementary-material id="pgen.1006374.s001" mimetype="application/eps" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006374.s001" xlink:type="simple">
<label>S1 Fig</label>
<caption>
<title>Protein comparison 1.</title>
<p><bold>Alignment of CnSec14-1p, ScSec14p and HsSec14-2p.</bold> The CLUSTAL 2.1 alignment of <italic>C</italic>. <italic>neoformans</italic>, <italic>S</italic>. <italic>cerevisiae</italic> and <italic>H</italic>. <italic>sapiens</italic> Sec14 proteins is shown and the NGx04 resistance conferring amino acids highlighted in red.</p>
<p>(EPS)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006374.s002" mimetype="application/eps" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006374.s002" xlink:type="simple">
<label>S2 Fig</label>
<caption>
<title>Protein comparison 2.</title>
<p><bold>Alignment of ScSec14p, CnSec14-1p and CnSec14-2p.</bold>The CLUSTAL 2.1 alignment of <italic>S</italic>. <italic>cerevisiae</italic> Sec14p and <italic>C</italic>. <italic>neoformans</italic> CnSec14-1p and CnSec14-2p is shown. Red boxes represent conserved amino acids involved in NGx04 binding in the three proteins, blue boxes represent non-conserved amino acids.</p>
<p>(EPS)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006374.s003" mimetype="application/eps" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006374.s003" xlink:type="simple">
<label>S3 Fig</label>
<caption>
<title>Anti-fungal resistance testing.</title>
<p><bold>Inhibition of fluconazole resistant <italic>C</italic>. <italic>neoformans</italic>.</bold> NGx04 and close analogues were tested against the FLU-resistant <italic>C</italic>. <italic>neoformans</italic> BPY22 [<xref ref-type="bibr" rid="pgen.1006374.ref045">45</xref>] in a 48 h proliferation assay and MIC-2 (50% inhibition) and MIC-0 (no visible fungal growth) determined. Values are given in μM as mean of tree replicates. Fluconazole was included as control to show hyper-resistance of BPY22.</p>
<p>(EPS)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006374.s004" mimetype="application/eps" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006374.s004" xlink:type="simple">
<label>S4 Fig</label>
<caption>
<title>Resistance mapping.</title>
<p><bold>Functional variomics screen for NGx04-resistant mutants.</bold> Statistics of the primary screen (genome-wide pool) and the secondary screen (SEC14 pool) are displayed. 1.5 OD<sub>600</sub> of the corresponding pools were plated on a 15 cm SD agar dish containing 150 μM NGx04, resistant clones isolated and analyzed by sequencing of the expressed ORF. Numbers in parenthesis display the frequency of the isolated ORFs.</p>
<p>(EPS)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006374.s005" mimetype="application/eps" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006374.s005" xlink:type="simple">
<label>S5 Fig</label>
<caption>
<title>Evolutionary divergence.</title>
<p><bold>Complementation of yeast SEC14.</bold> A heterozygous <italic>SEC14/sec14 S</italic>. <italic>cerevisiae</italic> strain was transformed with the human SEC14 homologue (XP_011510441.1) under the control of the ADH1 promotor. Transformants were isolated, subjected to sporulation, tetrads dissected and analysed for viability. 18 tetrads are shown (horizontal). Only two viable spores per tetrad were found, indicating no genetic complementation.</p>
<p>(EPS)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006374.s006" mimetype="application/eps" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006374.s006" xlink:type="simple">
<label>S6 Fig</label>
<caption>
<title>Effectiveness of growth inhibition.</title>
<p><bold>Fungicidal vs fungistatic effects of ergolines.</bold> Ergolines were tested at 16 μg/ml final concentration for 24 hrs. against FLU-sensitive (DSY4982) and FLU-resistant (BPY22 and BPY17) <italic>C</italic>. <italic>neoformans</italic> isolates [<xref ref-type="bibr" rid="pgen.1006374.ref045">45</xref>] for fungicidal activity and Colony Forming Units in presence (NGxXX) and in absence (inoculum) of compound are displayed as mean of three replicates. Detection limit of the assay was 10<sup>2</sup> cells/ml. This value was attributed to samples in which this detection limit was reached.</p>
<p>(EPS)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006374.s007" mimetype="application/eps" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006374.s007" xlink:type="simple">
<label>S7 Fig</label>
<caption>
<title>Physicochemical properties of ergolines.</title>
<p><bold>Rat liver microsome and artificial membrane permeability assay.</bold> NGx04 and close analogues were tested for metabolic stability (CYP MetCL) and artificial membrane permeability (logPAMPA) in duplicates. Value pairs are color coded and binning is indicated.</p>
<p>(EPS)</p>
</caption>
</supplementary-material>
<supplementary-material id="pgen.1006374.s008" mimetype="application/eps" position="float" xlink:href="info:doi/10.1371/journal.pgen.1006374.s008" xlink:type="simple">
<label>S8 Fig</label>
<caption>
<title>Anti-fungal testing.</title>
<p><bold>Fungal pathogen assay.</bold> NGx04 and close analogues were tested against <italic>C</italic>. <italic>albicans</italic> (ATCC 24433), <italic>A</italic>. <italic>fumigatus</italic> (ATCC MYA-3627), <italic>R</italic>. <italic>oryzae</italic> (ATCC MYA-4621) and <italic>F</italic>. <italic>solani</italic> (ATCC MYA-3636) in a 72 h proliferation assay and MIC-2 (50% inhibition) and MIC-0 (no visible fungal growth) determined. Values are given in μM as mean of tree replicates. Amphotericin B was included as positive control.</p>
<p>(EPS)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>We would like to acknowledge the Novartis HIP HOP team, T. Aust, J. Eichenberger, N. Hartmann, C. Wache-Mainier and S. Schuierer for profiling and analyzing the compounds used in this study. And we would like to thank F. Ischer for performing fungal inhibition assays.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pgen.1006374.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Brown</surname> <given-names>GD</given-names></name>, <name name-style="western"><surname>Denning</surname> <given-names>DW</given-names></name>, <name name-style="western"><surname>Gow</surname> <given-names>NAR</given-names></name>, <name name-style="western"><surname>Levitz</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Netea</surname> <given-names>MG</given-names></name>, <name name-style="western"><surname>White</surname> <given-names>TC</given-names></name>. <article-title>Hidden Killers: Human Fungal Infections</article-title>. <source>Science Translational Medicine</source>. <year>2012</year>;<volume>4</volume>(<issue>165</issue>):<fpage>165rv13</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/scitranslmed.3004404" xlink:type="simple">10.1126/scitranslmed.3004404</ext-link></comment> <object-id pub-id-type="pmid">23253612</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Arendrup MC</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Holm</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Nielsen</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Nielsen</surname> <given-names>SD</given-names></name>, <name name-style="western"><surname>Knudsen</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Drenck</surname> <given-names>NE</given-names></name>, <name name-style="western"><surname>Christensen</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Johansen</surname> <given-names>HK</given-names></name>. <article-title>Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia</article-title>. <source>Journal of Clinical Microbiology</source> <year>2011</year>;<volume>49</volume>(<issue>9</issue>):<fpage>9</fpage>.</mixed-citation></ref>
<ref id="pgen.1006374.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tripathi</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Meena</surname> <given-names>K.</given-names></name> <article-title>Genomic identification of potential targets unique to Candida albicans for the discovery of antifungal agents</article-title>. <source>Curr Drug Targets</source>. <year>2014</year>;<volume>15</volume>(<issue>1</issue>):<fpage>136</fpage>–<lpage>49</lpage>. <object-id pub-id-type="pmid">24102473</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Balloy</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Chignard</surname> <given-names>M.</given-names></name> <article-title>The innate immune response to Aspergillus fumigatus</article-title>. <source>Microbes and Infection</source>. <year>2009</year>;<volume>11</volume>(<issue>12</issue>):<fpage>919</fpage>–<lpage>27</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.micinf.2009.07.002" xlink:type="simple">10.1016/j.micinf.2009.07.002</ext-link></comment> <object-id pub-id-type="pmid">19615460</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hope</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Natarajan</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Goodwin</surname> <given-names>L</given-names></name>. <article-title>Invasive fungal infections</article-title>. <source>Clinical Medicine</source>. <year>2013</year>;<volume>13</volume>(<issue>5</issue>):<fpage>507</fpage>–<lpage>10</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.7861/clinmedicine.13-5-507" xlink:type="simple">10.7861/clinmedicine.13-5-507</ext-link></comment> <object-id pub-id-type="pmid">24115712</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Odds</surname> <given-names>FC</given-names></name>. <article-title>Antifungal agents: their diversity and increasing sophistication</article-title>. <source>Mycologist</source>. <year>2003</year>;<volume>17</volume>(<issue>02</issue>):<fpage>51</fpage>–<lpage>5</lpage>.</mixed-citation></ref>
<ref id="pgen.1006374.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sheng</surname> <given-names>Z</given-names></name>. <article-title>New Lead Structures in Antifungal Drug Discovery</article-title>. <source>Curr Med Chem</source> <year>2011</year>;<volume>18</volume>(<issue>5</issue>):<fpage>768</fpage>.</mixed-citation></ref>
<ref id="pgen.1006374.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Denning</surname> <given-names>DWH</given-names></name>, <name name-style="western"><surname>William</surname> <given-names>W</given-names></name>. <article-title>Therapy for fungal diseases: opportunities and priorities</article-title>. <source>Trends in Microbiology</source>. <year>2010</year>;<volume>18</volume>(<issue>5</issue>):<fpage>195</fpage>–<lpage>204</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.tim.2010.02.004" xlink:type="simple">10.1016/j.tim.2010.02.004</ext-link></comment> <object-id pub-id-type="pmid">20207544</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Manzoni</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Franco</surname> <given-names>R.</given-names></name>, <name name-style="western"><surname>Stronati</surname> <given-names>W.</given-names></name>, <name name-style="western"><surname>Cohen-Wolkowiez</surname> <given-names>JA.</given-names></name> <article-title>Echinocandins for the nursery: an update</article-title>. <source>Curr Drug Metab</source>. <year>2013</year>;<volume>14</volume>(<issue>2</issue>):<fpage>203</fpage>–<lpage>7</lpage>. <object-id pub-id-type="pmid">22935065</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lepak</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Marchillo</surname> <given-names>K.</given-names></name>, <name name-style="western"><surname>Andes</surname> <given-names>DR.</given-names></name> <article-title>Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2015</year>;<volume>59</volume>(<issue>2</issue>):<fpage>1265</fpage>–<lpage>72</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.04445-14" xlink:type="simple">10.1128/AAC.04445-14</ext-link></comment> <object-id pub-id-type="pmid">25512406</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chayakulkeeree</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Johnston</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Oei</surname> <given-names>JB</given-names></name>, <name name-style="western"><surname>Lev</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Williamson</surname> <given-names>PR</given-names></name>, <name name-style="western"><surname>Wilson</surname> <given-names>CF</given-names></name>, <etal>et al</etal>. <article-title>SEC14 is a specific requirement for secretion of phospholipase B1 and pathogenicity of Cryptococcus neoformans</article-title>. <source>Molecular Microbiology</source>. <year>2011</year>;<volume>80</volume>(<issue>4</issue>):<fpage>1088</fpage>–<lpage>101</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1365-2958.2011.07632.x" xlink:type="simple">10.1111/j.1365-2958.2011.07632.x</ext-link></comment> <object-id pub-id-type="pmid">21453402</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rodrigues</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Djordjevic</surname> <given-names>JT.</given-names></name> <article-title>Unravelling secretion in Cryptococcus neoformans: more than one way to skin a cat</article-title>. <source>Mycopathologia</source>. <year>2012</year>;<volume>173</volume>(<issue>5–6</issue>):<fpage>407</fpage>–<lpage>18</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s11046-011-9468-9" xlink:type="simple">10.1007/s11046-011-9468-9</ext-link></comment> <object-id pub-id-type="pmid">21898146</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cox</surname> <given-names>GM</given-names></name>, <name name-style="western"><surname>McDade</surname> <given-names>HC</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>SCA</given-names></name>, <name name-style="western"><surname>Tucker</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Gottfredsson</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Wright</surname> <given-names>LC</given-names></name>, <etal>et al</etal>. <article-title>Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans</article-title>. <source>Molecular Microbiology</source>. <year>2001</year>;<volume>39</volume>(<issue>1</issue>):<fpage>166</fpage>–<lpage>75</lpage>. <object-id pub-id-type="pmid">11123698</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Djordjevic</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Del Poeta</surname> <given-names>M.</given-names></name>, <name name-style="western"><surname>Sorrell</surname> <given-names>TC.</given-names></name>, <name name-style="western"><surname>Turner</surname> <given-names>KM.</given-names></name>, <name name-style="western"><surname>Wright</surname> <given-names>LC.</given-names></name> <article-title>Secretion of cryptococcal phospholipase B1 (PLB1) is regulated by a glycosylphosphatidylinositol (GPI) anchor</article-title>. <source>Biochem J</source>. <year>2005</year>;<volume>389</volume>(<issue>Pt 3</issue>):<fpage>803</fpage>–<lpage>14</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1042/BJ20050063" xlink:type="simple">10.1042/BJ20050063</ext-link></comment> <object-id pub-id-type="pmid">15826239</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Siafakas</surname> <given-names>AR</given-names></name>, <name name-style="western"><surname>Wright</surname> <given-names>LC</given-names></name>, <name name-style="western"><surname>Sorrell</surname> <given-names>TC</given-names></name>, <name name-style="western"><surname>Djordjevic</surname> <given-names>JT</given-names></name>. <article-title>Lipid Rafts in Cryptococcus neoformans Concentrate the Virulence Determinants Phospholipase B1 and Cu/Zn Superoxide Dismutase</article-title>. <source>Eukaryotic Cell</source>. <year>2006</year>;<volume>5</volume>(<issue>3</issue>):<fpage>488</fpage>–<lpage>98</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/EC.5.3.488-498.2006" xlink:type="simple">10.1128/EC.5.3.488-498.2006</ext-link></comment> <object-id pub-id-type="pmid">16524904</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Waterman</surname> <given-names>SR</given-names></name>, <name name-style="western"><surname>Hacham</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Panepinto</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Hu</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Shin</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Williamson</surname> <given-names>PR</given-names></name>. <article-title>Cell Wall Targeting of Laccase of Cryptococcus neoformans during Infection of Mice</article-title>. <source>Infection and Immunity</source>. <year>2007</year>;<volume>75</volume>(<issue>2</issue>):<fpage>714</fpage>–<lpage>22</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/IAI.01351-06" xlink:type="simple">10.1128/IAI.01351-06</ext-link></comment> <object-id pub-id-type="pmid">17101662</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhu</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Gibbons</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Garcia-Rivera</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Casadevall</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Williamson</surname> <given-names>PR</given-names></name>. <article-title>Laccase of Cryptococcus neoformans Is a Cell Wall-Associated Virulence Factor</article-title>. <source>Infection and Immunity</source>. <year>2001</year>;<volume>69</volume>(<issue>9</issue>):<fpage>5589</fpage>–<lpage>96</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/IAI.69.9.5589-5596.2001" xlink:type="simple">10.1128/IAI.69.9.5589-5596.2001</ext-link></comment> <object-id pub-id-type="pmid">11500433</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nile</surname> <given-names>AH</given-names></name>, <name name-style="western"><surname>Tripathi</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Yuan</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Mousley</surname> <given-names>CJ</given-names></name>, <name name-style="western"><surname>Suresh</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Wallace</surname> <given-names>IM</given-names></name>, <etal>et al</etal>. <article-title>PITPs as targets for selectively interfering with phosphoinositide signaling in cells</article-title>. <source>Nat Chem Biol</source>. <year>2014</year>;<volume>10</volume>(<issue>1</issue>):<fpage>76</fpage>–<lpage>84</lpage>. <ext-link ext-link-type="uri" xlink:href="http://www.nature.com/nchembio/journal/v10/n1/abs/nchembio.1389.html#supplementary-information" xlink:type="simple">http://www.nature.com/nchembio/journal/v10/n1/abs/nchembio.1389.html#supplementary-information</ext-link>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nchembio.1389" xlink:type="simple">10.1038/nchembio.1389</ext-link></comment> <object-id pub-id-type="pmid">24292071</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Agúndez</surname> <given-names>JAG</given-names></name>, <name name-style="western"><surname>García-Martín</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Alonso-Navarro</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Jiménez-Jiménez</surname> <given-names>FJ</given-names></name>. <article-title>Anti-Parkinson's disease drugs and pharmacogenetic considerations</article-title>. <source>Expert Opinion on Drug Metabolism &amp; Toxicology</source>. <year>2013</year>;<volume>9</volume>(<issue>7</issue>):<fpage>859</fpage>–<lpage>74</lpage>.</mixed-citation></ref>
<ref id="pgen.1006374.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lamos</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>Levitt</surname> <given-names>DL</given-names></name>, <name name-style="western"><surname>Munir</surname> <given-names>KM</given-names></name>. <article-title>A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters</article-title>. <source>Primary Care Diabetes</source>. <year>2016</year>;<volume>10</volume>(<issue>1</issue>):<fpage>60</fpage>–<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.pcd.2015.10.008" xlink:type="simple">10.1016/j.pcd.2015.10.008</ext-link></comment> <object-id pub-id-type="pmid">26670921</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nyholm</surname> <given-names>D</given-names></name>. <article-title>Pharmacokinetic Optimisation in the Treatment of Parkinson’s Disease</article-title>. <source>Clinical Pharmacokinetics</source>. <year>2013</year>;<volume>45</volume>(<issue>2</issue>):<fpage>109</fpage>–<lpage>36</lpage>.</mixed-citation></ref>
<ref id="pgen.1006374.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Patniyot</surname> <given-names>IR</given-names></name>, <name name-style="western"><surname>Gelfand</surname> <given-names>AA</given-names></name>. <article-title>Acute Treatment Therapies for Pediatric Migraine: A Qualitative Systematic Review. Headache</article-title>: <source>The Journal of Head and Face Pain</source>. <year>2016</year>;<volume>56</volume>(<issue>1</issue>):<fpage>49</fpage>–<lpage>70</lpage>.</mixed-citation></ref>
<ref id="pgen.1006374.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rodrigues</surname> <given-names>TM</given-names></name>, <name name-style="western"><surname>Castro Caldas</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Ferreira</surname> <given-names>JJ</given-names></name>. <article-title>Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson's disease: Systematic review and meta-analysis</article-title>. <source>Parkinsonism &amp; Related Disorders</source>. <year>2016</year>.</mixed-citation></ref>
<ref id="pgen.1006374.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Saper</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Evans</surname> <given-names>RW</given-names></name>. <article-title>Oral Methylergonovine Maleate for Refractory Migraine and Cluster Headache Prevention. Headache</article-title>: <source>The Journal of Head and Face Pain</source>. <year>2013</year>;<volume>53</volume>(<issue>2</issue>):<fpage>378</fpage>–<lpage>81</lpage>.</mixed-citation></ref>
<ref id="pgen.1006374.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Werneke</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>TURNER</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>PRIEBE</surname> <given-names>S</given-names></name>. <article-title>Complementary medicines in psychiatry</article-title>. <source>Review of effectiveness and safety</source>. <year>2006</year>;<volume>188</volume>(<issue>2</issue>):<fpage>109</fpage>–<lpage>21</lpage>.</mixed-citation></ref>
<ref id="pgen.1006374.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hoepfner</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Helliwell</surname> <given-names>SB</given-names></name>, <name name-style="western"><surname>Sadlish</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Schuierer</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Filipuzzi</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Brachat</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>High-resolution chemical dissection of a model eukaryote reveals targets, pathways and gene functions</article-title>. <source>Microbiological Research</source>. <year>2014</year>;<volume>169</volume>(<issue>2–3</issue>):<fpage>107</fpage>–<lpage>20</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.micres.2013.11.004" xlink:type="simple">10.1016/j.micres.2013.11.004</ext-link></comment> <object-id pub-id-type="pmid">24360837</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Richie</surname> <given-names>DL</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>KV</given-names></name>, <name name-style="western"><surname>Studer</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Prindle</surname> <given-names>VC</given-names></name>, <name name-style="western"><surname>Aust</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Riedl</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Identification and Evaluation of Novel Acetolactate Synthase Inhibitors as Antifungal Agents</article-title>. <source>Antimicrobial Agents and Chemotherapy</source>. <year>2013</year>;<volume>57</volume>(<issue>5</issue>):<fpage>2272</fpage>–<lpage>80</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.01809-12" xlink:type="simple">10.1128/AAC.01809-12</ext-link></comment> <object-id pub-id-type="pmid">23478965</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Giaever</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Flaherty</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Kumm</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Proctor</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Nislow</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Jaramillo</surname> <given-names>DF</given-names></name>, <etal>et al</etal>. <article-title>Chemogenomic profiling: Identifying the functional interactions of small molecules in yeast</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>. <year>2004</year>;<volume>101</volume>(<issue>3</issue>):<fpage>793</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.0307490100" xlink:type="simple">10.1073/pnas.0307490100</ext-link></comment> <object-id pub-id-type="pmid">14718668</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fang</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kearns</surname> <given-names>BG.</given-names></name>, <name name-style="western"><surname>Gedvilaite</surname> <given-names>A.</given-names></name>, <name name-style="western"><surname>Kagiwada</surname> <given-names>S.</given-names></name>, <name name-style="western"><surname>Kearns</surname> <given-names>M.</given-names></name>, <name name-style="western"><surname>Fung</surname> <given-names>MK.</given-names></name>, <name name-style="western"><surname>Bankaitis</surname> <given-names>VA.</given-names></name> <article-title>Kes1p shares homology with human oxysterol binding protein and participates in a novel regulatory pathway for yeast Golgi-derived transport vesicle biogenesis</article-title>. <source>EMBO J</source>. <year>1996</year>;<volume>15</volume>(<issue>23</issue>):<fpage>6447</fpage>–<lpage>59</lpage>. <object-id pub-id-type="pmid">8978672</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Rivas</surname> <given-names>MP</given-names></name>, <name name-style="western"><surname>Fang</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Marchena</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Mehrotra</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Chaudhary</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Analysis of oxysterol binding protein homologue Kes1p function in regulation of Sec14p-dependent protein transport from the yeast Golgi complex</article-title>. <source>The Journal of Cell Biology</source>. <year>2002</year>;<volume>157</volume>(<issue>1</issue>):<fpage>63</fpage>–<lpage>78</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1083/jcb.200201037" xlink:type="simple">10.1083/jcb.200201037</ext-link></comment> <object-id pub-id-type="pmid">11916983</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sreenivas</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Patton-Vogt</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Bruno</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Griac</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Henry</surname> <given-names>SA</given-names></name>. <article-title>A Role for Phospholipase D (Pld1p) in Growth, Secretion, and Regulation of Membrane Lipid Synthesis in Yeast</article-title>. <source>Journal of Biological Chemistry</source>. <year>1998</year>;<volume>273</volume>(<issue>27</issue>):<fpage>16635</fpage>–<lpage>8</lpage>. <object-id pub-id-type="pmid">9642212</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xie</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Rivas</surname></name>, <name name-style="western"><surname>Faulkner</surname></name>, <name name-style="western"><surname>Sternweis</surname></name>, <name name-style="western"><surname>Engebrecht</surname></name>, <name name-style="western"><surname>Bankaitis</surname></name>. <article-title>Phospholipase D activity is required for suppression of yeast phosphatidylinositol transfer protein defects</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>1998</year>;<volume>95</volume>(<issue>21</issue>):<fpage>12346</fpage>–<lpage>51</lpage>. <object-id pub-id-type="pmid">9770489</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nikawa</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Tsukagoshi</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Yamashita</surname> <given-names>S</given-names></name>. <article-title>Isolation and characterization of two distinct myo-inositol transporter genes of Saccharomyces cerevisiae</article-title>. <source>Journal of Biological Chemistry</source>. <year>1991</year>;<volume>266</volume>(<issue>17</issue>):<fpage>11184</fpage>–<lpage>91</lpage>. <object-id pub-id-type="pmid">2040626</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Huang</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Cui</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>A Functional Variomics Tool for Discovering Drug-Resistance Genes and Drug Targets</article-title>. <source>Cell Reports</source>. <year>2013</year>;<volume>3</volume>(<issue>2</issue>):<fpage>577</fpage>–<lpage>85</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.celrep.2013.01.019" xlink:type="simple">10.1016/j.celrep.2013.01.019</ext-link></comment> <object-id pub-id-type="pmid">23416056</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bankaitis</surname> <given-names>VA</given-names></name>, <name name-style="western"><surname>Mousley</surname> <given-names>CJ</given-names></name>, <name name-style="western"><surname>Schaaf</surname> <given-names>G</given-names></name>. <article-title>The Sec14 superfamily and mechanisms for crosstalk between lipid metabolism and lipid signaling</article-title>. <source>Trends in Biochemical Sciences</source>. <year>2010</year>;<volume>35</volume>(<issue>3</issue>):<fpage>150</fpage>–<lpage>60</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.tibs.2009.10.008" xlink:type="simple">10.1016/j.tibs.2009.10.008</ext-link></comment> <object-id pub-id-type="pmid">19926291</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schaaf</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Ortlund</surname> <given-names>EA</given-names></name>, <name name-style="western"><surname>Tyeryar</surname> <given-names>KR</given-names></name>, <name name-style="western"><surname>Mousley</surname> <given-names>CJ</given-names></name>, <name name-style="western"><surname>Ile</surname> <given-names>KE</given-names></name>, <name name-style="western"><surname>Garrett</surname> <given-names>TA</given-names></name>, <etal>et al</etal>. <article-title>Functional Anatomy of Phospholipid Binding and Regulation of Phosphoinositide Homeostasis by Proteins of the Sec14 Superfamily</article-title>. <source>Molecular Cell</source>. <year>2008</year>;<volume>29</volume>(<issue>2</issue>):<fpage>191</fpage>–<lpage>206</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.molcel.2007.11.026" xlink:type="simple">10.1016/j.molcel.2007.11.026</ext-link></comment> <object-id pub-id-type="pmid">18243114</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Khan</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>McGrath</surname> <given-names>KR</given-names></name>, <name name-style="western"><surname>Dorosheva</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Bankaitis</surname> <given-names>VA</given-names></name>, <name name-style="western"><surname>Tripathi</surname> <given-names>A</given-names></name>. <article-title>Structural elements that govern Sec14-like PITP sensitivities to potent small molecule inhibitors</article-title>. <source>Journal of Lipid Research</source>. <year>2016</year>;<volume>57</volume>(<issue>4</issue>):<fpage>650</fpage>–<lpage>62</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1194/jlr.M066381" xlink:type="simple">10.1194/jlr.M066381</ext-link></comment> <object-id pub-id-type="pmid">26921357</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Barretina</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Caponigro</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Stransky</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Venkatesan</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Margolin</surname> <given-names>AA</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity</article-title>. <source>Nature</source>. <year>2012</year>;<volume>483</volume>(<issue>7391</issue>):<fpage>603</fpage>–<lpage>307</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature11003" xlink:type="simple">10.1038/nature11003</ext-link></comment> <object-id pub-id-type="pmid">22460905</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Qin</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Zheng</surname> <given-names>X</given-names></name>. <article-title>DISIS: Prediction of Drug Response through an Iterative Sure Independence Screening</article-title>. <source>PLoS ONE</source>. <year>2015</year>;<volume>10</volume>(<issue>3</issue>):<fpage>e0120408</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0120408" xlink:type="simple">10.1371/journal.pone.0120408</ext-link></comment> <object-id pub-id-type="pmid">25794193</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Miret</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>De Groene</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>Klaffke</surname> <given-names>W</given-names></name>. <article-title>Comparison of In Vitro Assays of Cellular Toxicity in the Human Hepatic Cell Line HepG2</article-title>. <source>Journal of Biomolecular Screening</source>. <year>2006</year>;<volume>11</volume>(<issue>2</issue>):<fpage>184</fpage>–<lpage>93</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1177/1087057105283787" xlink:type="simple">10.1177/1087057105283787</ext-link></comment> <object-id pub-id-type="pmid">16314402</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Brandt</surname> <given-names>ME</given-names></name>, <name name-style="western"><surname>Pfaller</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Hajjeh</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>Hamill</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Pappas</surname> <given-names>PG</given-names></name>, <name name-style="western"><surname>Reingold</surname> <given-names>AL</given-names></name>, <etal>et al</etal>. <article-title>Trends in Antifungal Drug Susceptibility of Cryptococcus neoformans Isolates in the United States: 1992 to 1994 and 1996 to 1998</article-title>. <source>Antimicrobial Agents and Chemotherapy</source>. <year>2001</year>;<volume>45</volume>(<issue>11</issue>):<fpage>3065</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.45.11.3065-3069.2001" xlink:type="simple">10.1128/AAC.45.11.3065-3069.2001</ext-link></comment> <object-id pub-id-type="pmid">11600357</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bicanic T</surname> <given-names>MG</given-names></name>, <name name-style="western"><surname>Rebe</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Williams</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Loyse</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Wood</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Hayes</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Jaffar</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Harrison</surname> <given-names>T</given-names></name>. <article-title>Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2009</year>;<volume>51</volume>(<issue>2</issue>):<fpage>5</fpage>.</mixed-citation></ref>
<ref id="pgen.1006374.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fera</surname> <given-names>MT</given-names></name>, <name name-style="western"><surname>La Camera</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>De Sarro</surname> <given-names>A</given-names></name>. <article-title>New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance</article-title>. <source>Expert Review of Anti-infective Therapy</source>. <year>2009</year>;<volume>7</volume>(<issue>8</issue>):<fpage>981</fpage>–<lpage>98</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1586/eri.09.67" xlink:type="simple">10.1586/eri.09.67</ext-link></comment> <object-id pub-id-type="pmid">19803707</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sanglard</surname> <given-names>D</given-names></name>. <article-title>Resistance of human fungal pathogens to antifungal drugs</article-title>. <source>Current Opinion in Microbiology</source>. <year>2002</year>;<volume>5</volume>(<issue>4</issue>):<fpage>379</fpage>–<lpage>85</lpage>. <object-id pub-id-type="pmid">12160856</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Posteraro</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Sanguinetti</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Sanglard</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>La Sorda</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Boccia</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Romano</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Identification and characterization of a Cryptococcus neoformans ATP binding cassette (ABC) transporter-encoding gene, CnAFR1, involved in the resistance to fluconazole</article-title>. <source>Molecular Microbiology</source>. <year>2003</year>;<volume>47</volume>(<issue>2</issue>):<fpage>357</fpage>–<lpage>71</lpage>. <object-id pub-id-type="pmid">12519188</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vendetti</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Bryan</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Zaoutis</surname> <given-names>TE</given-names></name>, <name name-style="western"><surname>Damianos</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Fisher</surname> <given-names>BT</given-names></name>. <article-title>Comparative effectiveness of fungicidal vs. fungistatic therapies for the treatment of paediatric candidaemia</article-title>. <source>Mycoses</source>. <year>2016</year>;<volume>59</volume>(<issue>3</issue>):<fpage>173</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/myc.12449" xlink:type="simple">10.1111/myc.12449</ext-link></comment> <object-id pub-id-type="pmid">26692326</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname> <given-names>T-B</given-names></name>, <name name-style="western"><surname>Perlin</surname> <given-names>DS</given-names></name>, <name name-style="western"><surname>Xue</surname> <given-names>C</given-names></name>. <article-title>Molecular mechanisms of cryptococcal meningitis</article-title>. <source>Virulence</source>. <year>2012</year>;<volume>3</volume>(<issue>2</issue>):<fpage>173</fpage>–<lpage>81</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4161/viru.18685" xlink:type="simple">10.4161/viru.18685</ext-link></comment> <object-id pub-id-type="pmid">22460646</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vu</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Tham</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Uhrig</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>GR</given-names></name>, <name name-style="western"><surname>Na Pombejra</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Jamklang</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Invasion of the Central Nervous System by Cryptococcus neoformans Requires a Secreted Fungal Metalloprotease</article-title>. <source>mBio</source>. <year>2014</year>;<volume>5</volume>(<issue>3</issue>):<fpage>e01101</fpage>–<lpage>14</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/mBio.01101-14" xlink:type="simple">10.1128/mBio.01101-14</ext-link></comment> <object-id pub-id-type="pmid">24895304</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Alspaugh</surname> <given-names>JA</given-names></name>. <article-title>Virulence mechanisms and Cryptococcus neoformans pathogenesis</article-title>. <source>Fungal Genetics and Biology</source>. <year>2014</year>;(<issue>78</issue>):<fpage>55</fpage>–<lpage>8</lpage>.</mixed-citation></ref>
<ref id="pgen.1006374.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Giaever</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Shoemaker</surname> <given-names>DD</given-names></name>, <name name-style="western"><surname>Jones</surname> <given-names>TW</given-names></name>, <name name-style="western"><surname>Liang</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Winzeler</surname> <given-names>EA</given-names></name>, <name name-style="western"><surname>Astromoff</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Genomic profiling of drug sensitivities via induced haploinsufficiency</article-title>. <source>Nat Genet</source>. <year>1999</year>;<volume>21</volume>(<issue>3</issue>):<fpage>278</fpage>–<lpage>83</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/6791" xlink:type="simple">10.1038/6791</ext-link></comment> <object-id pub-id-type="pmid">10080179</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref051"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lum</surname> <given-names>PY</given-names></name>, <name name-style="western"><surname>Armour</surname> <given-names>CD</given-names></name>, <name name-style="western"><surname>Stepaniants</surname> <given-names>SB</given-names></name>, <name name-style="western"><surname>Cavet</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Wolf</surname> <given-names>MK</given-names></name>, <name name-style="western"><surname>Butler</surname> <given-names>JS</given-names></name>, <etal>et al</etal>. <article-title>Discovering Modes of Action for Therapeutic Compounds Using a Genome-Wide Screen of Yeast Heterozygotes</article-title>. <source>Cell</source>. <year>2004</year>;<volume>116</volume>(<issue>1</issue>):<fpage>121</fpage>–<lpage>37</lpage>. <object-id pub-id-type="pmid">14718172</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref052"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Roemer</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Singh Sheo</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Parish Craig</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Harris</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Confronting the Challenges of Natural Product-Based Antifungal Discovery</article-title>. <source>Chemistry &amp; Biology</source>. <year>2011</year>;<volume>18</volume>(<issue>2</issue>):<fpage>148</fpage>–<lpage>64</lpage>.</mixed-citation></ref>
<ref id="pgen.1006374.ref053"><label>53</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Routt</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Xie</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Cui</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Fang</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kearns</surname> <given-names>MA</given-names></name>, <etal>et al</etal>. <article-title>Identification of a Novel Family of Nonclassic Yeast Phosphatidylinositol Transfer Proteins Whose Function Modulates Phospholipase D Activity and Sec14p-independent Cell Growth</article-title>. <source>Molecular Biology of the Cell</source>. <year>2000</year>;<volume>11</volume>(<issue>6</issue>):<fpage>1989</fpage>–<lpage>2005</lpage>. <object-id pub-id-type="pmid">10848624</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref054"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Onge</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Schlecht</surname> <given-names>U.</given-names></name>, <name name-style="western"><surname>Scharfe</surname> <given-names>C.</given-names></name>, <name name-style="western"><surname>Evangelista</surname> <given-names>M.</given-names></name> <article-title>Forward Chemical Genetics in Yeast for Discovery of Chemical Probes Targeting Metabolism</article-title>. <source>Molecules</source>. <year>2012</year>;<volume>17</volume>(<issue>11</issue>):<fpage>13098</fpage>–<lpage>115</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3390/molecules171113098" xlink:type="simple">10.3390/molecules171113098</ext-link></comment> <object-id pub-id-type="pmid">23128089</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref055"><label>55</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sha</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Phillips</surname> <given-names>SE</given-names></name>, <name name-style="western"><surname>Bankaitis</surname> <given-names>VA</given-names></name>, <name name-style="western"><surname>Luo</surname> <given-names>M</given-names></name>. <article-title>Crystal structure of the Saccharomyces cerevisiae phosphatidylinositol- transfer protein</article-title>. <source>Nature</source>. <year>1998</year>;<volume>391</volume>(<issue>6666</issue>):<fpage>506</fpage>–<lpage>10</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/35179" xlink:type="simple">10.1038/35179</ext-link></comment> <object-id pub-id-type="pmid">9461221</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref056"><label>56</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bankaitis</surname> <given-names>VA</given-names></name>, <name name-style="western"><surname>Aitken</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Cleves</surname> <given-names>AE</given-names></name>, <name name-style="western"><surname>Dowhan</surname> <given-names>W</given-names></name>. <article-title>An essential role for a phospholipid transfer protein in yeast Golgi function</article-title>. <source>Nature</source>. <year>1990</year>;<volume>347</volume>(<issue>6293</issue>):<fpage>561</fpage>–<lpage>2</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/347561a0" xlink:type="simple">10.1038/347561a0</ext-link></comment> <object-id pub-id-type="pmid">2215682</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref057"><label>57</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Phillips</surname> <given-names>SE</given-names></name>, <name name-style="western"><surname>Vincent</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Rizzieri</surname> <given-names>KE</given-names></name>, <name name-style="western"><surname>Schaaf</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Bankaitis</surname> <given-names>VA</given-names></name>, <name name-style="western"><surname>Gaucher</surname> <given-names>EA</given-names></name>. <article-title>The Diverse Biological Functions of Phosphatidylinositol Transfer Proteins in Eukaryotes</article-title>. <source>Critical Reviews in Biochemistry and Molecular Biology</source>. <year>2006</year>;<volume>41</volume>(<issue>1</issue>):<fpage>21</fpage>–<lpage>49</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1080/10409230500519573" xlink:type="simple">10.1080/10409230500519573</ext-link></comment> <object-id pub-id-type="pmid">16455519</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref058"><label>58</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee</surname> <given-names>AY</given-names></name>, <name name-style="western"><surname>St.Onge</surname> <given-names>RP</given-names></name>, <name name-style="western"><surname>Proctor</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Wallace</surname> <given-names>IM</given-names></name>, <name name-style="western"><surname>Nile</surname> <given-names>AH</given-names></name>, <name name-style="western"><surname>Spagnuolo</surname> <given-names>PA</given-names></name>, <etal>et al</etal>. <article-title>Mapping the Cellular Response to Small Molecules Using Chemogenomic Fitness Signatures</article-title>. <source>Science (New York, NY)</source>. <year>2014</year>;<volume>344</volume>(<issue>6180</issue>):<fpage>208</fpage>–<lpage>11</lpage>.</mixed-citation></ref>
<ref id="pgen.1006374.ref059"><label>59</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>De Grooth</surname> <given-names>ANJA</given-names></name>, <name name-style="western"><surname>van Dongen</surname> <given-names>PWJ</given-names></name>, <name name-style="western"><surname>Vree</surname> <given-names>TB</given-names></name>, <name name-style="western"><surname>Hekster</surname> <given-names>YA</given-names></name>, <name name-style="western"><surname>van Roosmalen</surname> <given-names>J</given-names></name>. <article-title>Ergot Alkaloids–Current Status and Review of Clinical and Therapeutic Use Compared with Other Oxytocics in Obstetrics and Gynaecology</article-title>. <source>Drugs</source>. <year>1998</year>;<volume>56</volume>:<fpage>523</fpage>–<lpage>35</lpage>. <object-id pub-id-type="pmid">9806101</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref060"><label>60</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tanret</surname> <given-names>C</given-names></name>. <article-title>Sur la presence d’un nouvel alkaloide, l’ergotinine, dans le seigle egoté</article-title>. <source>C R Acad Sci</source>. <year>1875</year>;<volume>81</volume>:<fpage>2</fpage>.</mixed-citation></ref>
<ref id="pgen.1006374.ref061"><label>61</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sinz</surname> <given-names>A</given-names></name>. <article-title>Die Bedeutung der Mutterkorn-Alkaloide als Arzneistoffe</article-title>. <source>Pharm Unserer Zeit</source>. <year>2008</year>;<volume>4</volume>:<fpage>4</fpage>.</mixed-citation></ref>
<ref id="pgen.1006374.ref062"><label>62</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Silberstein</surname> <given-names>SD</given-names></name>, <name name-style="western"><surname>McCrory</surname> <given-names>DC</given-names></name>. <article-title>Ergotamine and Dihydroergotamine: History, Pharmacology, and Efficacy</article-title>. <source>Headache: The Journal of Head and Face Pain</source>. <year>2003</year>;<volume>43</volume>(<issue>2</issue>):<fpage>144</fpage>–<lpage>66</lpage>.</mixed-citation></ref>
<ref id="pgen.1006374.ref063"><label>63</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pierce</surname> <given-names>SE</given-names></name>, <name name-style="western"><surname>Davis</surname> <given-names>RW</given-names></name>, <name name-style="western"><surname>Nislow</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Giaever</surname> <given-names>G</given-names></name>. <article-title>Genome-wide analysis of barcoded Saccharomyces cerevisiae gene-deletion mutants in pooled cultures</article-title>. <source>Nat Protocols</source>. <year>2007</year>;<volume>2</volume>(<issue>11</issue>):<fpage>2958</fpage>–<lpage>74</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nprot.2007.427" xlink:type="simple">10.1038/nprot.2007.427</ext-link></comment> <object-id pub-id-type="pmid">18007632</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref064"><label>64</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gasteiger</surname> <given-names>C.</given-names> <suffix>JR</suffix></name>; <name name-style="western"><surname>Sadowski</surname> <given-names>J.</given-names></name> <article-title>Automatic Generation of 3D Atomic Coordinates for Organic Molecules</article-title>. <source>Tetrahedron Comp Method</source>. <year>1990</year>;<volume>3</volume>:<fpage>548</fpage>.</mixed-citation></ref>
<ref id="pgen.1006374.ref065"><label>65</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Guagnano</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Kauffmann</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Wöhrle</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Stamm</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Ito</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Barys</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <article-title>FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor</article-title>. <source>Cancer Discovery</source>. <year>2012</year>;<volume>2</volume>(<issue>12</issue>):<fpage>1118</fpage>–<lpage>33</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/2159-8290.CD-12-0210" xlink:type="simple">10.1158/2159-8290.CD-12-0210</ext-link></comment> <object-id pub-id-type="pmid">23002168</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref066"><label>66</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Obach</surname> <given-names>RS</given-names></name>. <article-title>Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes</article-title>. <source>Drug Metabolism and Disposition</source>. <year>1999</year>;<volume>27</volume>(<issue>11</issue>):<fpage>1350</fpage>–<lpage>9</lpage>. <object-id pub-id-type="pmid">10534321</object-id></mixed-citation></ref>
<ref id="pgen.1006374.ref067"><label>67</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wohnsland</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Faller</surname> <given-names>B</given-names></name>. <article-title>High-Throughput Permeability pH Profile and High-Throughput Alkane/Water log P with Artificial Membranes</article-title>. <source>Journal of Medicinal Chemistry</source>. <year>2001</year>;<volume>44</volume>(<issue>6</issue>):<fpage>923</fpage>–<lpage>30</lpage>. <object-id pub-id-type="pmid">11300874</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>